Ethinyl Estradiol and Levonorgestrel
Brand names: Levonorgestrel And Ethinyl Estradiol · Active ingredient: Ethinyl Estradiol, Levonorgestrel
In short: Levonorgestrel and ethinyl estradiol tablets are indicated for use by females of reproductive potential to prevent pregnancy.
What is Ethinyl Estradiol and Levonorgestrel used for?
Levonorgestrel and ethinyl estradiol tablets are indicated for use by females of reproductive potential to prevent pregnancy.
⚠ Boxed warning (FDA's strongest warning)
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Levonorgestrel and ethinyl estradiol tablets, are contraindicated in women who are over 35 years of age and smoke .
Ethinyl Estradiol and Levonorgestrel dosage
Levonorgestrel and ethinyl estradiol tablets are dispensed in an Extended-Cycle Blister card . Levonorgestrel and ethinyl estradiol tablets should be started on a Sunday . For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.
Starting Levonorgestrel and ethinyl estradiol tablets in females with no current use of hormonal contraception (Sunday Start)
Important:
Consider the possibility of ovulation and conception prior to initiation of this product.
Tablet Color:
● Levonorgestrel and ethinyl estradiol active tablets are pink (Day 1 to Day 84). ● Levonorgestrel and ethinyl estradiol inactive tablets are white (Day 85 to Day 91). | Sunday Start:
For each 91-day course, take in the following order:
● Take the first pink tablet (0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol) on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, take the tablet on that day. Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms or spermicide) for the first 7 days of treatment.
● Take subsequent pink tablets once daily at the same time each day for a total of 84 days. ● Take one white tablet (inert) daily for the following 7 days and at the same time of day that active tablets were taken. A scheduled period should occur during the 7 days that the white tablets are taken. ● Begin the next and all subsequent 91-day courses of levonorgestrel and ethinyl estradiol tablets without interruption on the same day of the week (Sunday) on which the patient began her first dose. Follow the same schedule as the initial 91-day course: a pink tablet once a day for 84 days, and a white tablet once a day for 7 days. If the patient does not immediately start her next pill pack, instruct her to protect herself from pregnancy by using a non-hormonal back-up method of contraception until she has taken a pink tablet daily for 7 consecutive days.
Switching from another contraceptive method to levonorgestrel and ethinyl estradiol tablets | Start levonorgestrel and ethinyl estradiol tablets:
Another oral contraceptive | On the day when the new pack of the previous COC would have been started
● Transdermal patch | ● On the day when the next application would have been scheduled.
● Vaginal ring | ● On the day when the next insertion would have been scheduled.
● Injection | ● On the day when the next injection would have been scheduled.
● Intrauterine contraceptive (IUD) | ● On the day of removal. ● If the IUD is not removed on first day of the patient's menstrual cycle, additional non-hormonal contraception (such as condoms or spermicide) is needed for the first seven days of the first 91-day course. …
How to take Ethinyl Estradiol and Levonorgestrel — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Cigarette Smoking
Cigarette smoking increases the risk of serious cardiovascular events from COC use women who are over 35 years old and smoke should not use levonorgestrel and ethinyl estradiol tablets .
Venous Thromboembolism
The increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC .
Use During Pregnancy
Instruct females to stop further intake of levonorgestrel and ethinyl estradiol tablets if pregnancy is confirmed during treatment.
Sexually Transmitted Infections
Levonorgestrel and ethinyl estradiol tablets does not protect against HIV-infection (AIDS) and other sexually transmitted infections.
Dosing and Missed Pill Instructions
Patients should take one tablet daily by mouth at the same time every day. .
Instruct patients what to do in the event tablets are missed. See "What should I do if I miss any Levonorgestrel and ethinyl estradiol tablets pills" section in FDA-approved Instructions for Use . …
Warnings & precautions
Do not take this medicine if: Levonorgestrel and Ethinyl Estradiol Tablets is contraindicated in females who are known to have or develop the following conditions:
A high risk of arterial or venous thrombotic diseases. Examples include females who are known to:
Smoke, if over age 35 .
Have current or history of deep vein thrombosis or pulmonary embolism .
Have cerebrovascular disease .
Have coronary artery disease .
Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
Have inherited or acquired hypercoagulopathies .
Have uncontrolled hypertension or hypertension with vascular disease .
Have diabetes mellitus and are over age of 35, diabetes mellitus with hypertension or vascular disease or other end-organ damage, or diabetes mellitus of >20 years duration .
Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches .
• Current diagnosis of, or history of breast cancer, which may be hormone sensitive .
• Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis .
• Undiagnosed abnormal uterine bleeding .
• Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations .
Stop levonorgestrel and ethinyl estradiol tablets if an arterial or venous thrombotic/thromboembolic event occurs.
Stop levonorgestrel and ethinyl estradiol tablets if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.
Discontinue levonorgestrel and ethinyl estradiol tablets during prolonged immobilization. …
Ethinyl Estradiol and Levonorgestrel side effects
The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:
Serious cardiovascular events and stroke
Vascular events
Liver disease
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The clinical trial that evaluated the safety and efficacy of levonorgestrel and ethinyl estradiol tablets was a 12-month, randomized, multicenter, open-label study, which enrolled women aged 18 to 40, of whom 456 took at least one dose of levonorgestrel and ethinyl estradiol tablets (345.14 woman-years of exposure) .
Adverse Reactions Leading to Study Discontinuation: 14.9% of the women discontinued from the clinical trial due to an adverse reaction; the most common adverse reactions (≥ 1% of women) leading to discontinuation in the levonorgestrel and ethinyl estradiol tablets group were menorrhagia (5.7%), mood swings (1.9%), weight/appetite increase (1.5%), and acne (1.3%).
Common Adverse Reactions (≥ 2% of women): headache (20.6%), menorrhagia (11.6%), nausea (7.5%), dysmenorrhea (5.7%), acne (4.6%), migraine (4.4%), breast tenderness (3.5%), weight increased (3.1%), and depression (2.1%).
Serious Adverse Reactions: pulmonary embolus, cholecystitis. …
Drug interactions
The sections below provide information on substances for which data on drug interactions with COCs are available. There is little information available about the clinical effect of most drug interactions that may affect COCs. However, based on the known pharmacokinetic effects of these drugs, clinical strategies to minimize any potential adverse effect on contraceptive effectiveness or safety are suggested.
Consult the approved product labeling of all concurrently used drugs to obtain further information about interactions with COCs or the potential for metabolic enzyme or transporter system alterations.
No drug-drug interaction studies were conducted with levonorgestrel and ethinyl estradiol tablets.
Substances decreasing the plasma concentrations of COCs and potentially diminishing the efficacy of COCs:
Table 5 includes substances that demonstrated an important drug interaction with levonorgestrel and ethinyl estradiol tablets.
a Induction potency of St. John's wort may vary widely based on preparation.
Metabolic Enzyme Inducers
Clinical effect | • Concomitant use of COCs with metabolic enzyme inducers may decrease the plasma concentrations of the estrogen and/or progestin component of COCs. …
About this medicine
Levonorgestrel and ethinyl estradiol tablets USP are an extended-cycle combination oral contraceptive consisting of 84 pink, round, biconvex, film-coated, active tablets, each containing 0.15 mg of levonorgestrel USP, a synthetic progestin and 0.03 mg of ethinyl estradiol USP, an estrogen, and 7 white to off white, round, biconvex, inert tablets (without hormones).
The structural formulas for the active components are:
Levonorgestrel USP is chemically 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-, (-)-.
Ethinyl Estradiol USP is 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-.
Each pink active tablet contains the following inactive ingredients: croscarmellose sodium, FD & C Blue # 1, FD & C Red # 40, hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide.
Each white to off white inert tablet contains the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 58e85e02-93e7-42ba-b8f5-a36290c68423. Read the full official label on DailyMed.